Zacks.com on MSN1h
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A DealsPfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
American Merck & Co, known in Europe as MSD, has discontinued the development of vibostolimab and favezelimab, two ...
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...
MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies ...
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...
Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...
One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback